Regulation of chemosensitivity by the novel daughter strand gap suppressor MRNIP

UKRI FLF · United Kingdom government procurement

This opportunity is now closed. GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

Closed
Status

Opportunity Overview

All cells - even cancer cells - must copy their DNA if they are to divide, via a process called DNA 'replication' during which the genetic material is vulnerable to breakage, which in turn leads to cell death. Cancer cell killing is desirable, and therefore many chemotherapies work by targeting DNA replication to induce DNA breaks. Some cancers contain mutations in genes that function in DNA break repair, and these mutations render them sensitive to certain therapies. For example, the tumour suppressor genes BRCA1 and BRCA2 promote cancer cell survival by preventing the formation of toxic gaps in the DNA following chemotherapy treatment, and by helping repair therapy-induced DNA breaks. Patients with BRCA mutations often thus respond well to traditional chemotherapies like Cisplatin and the more advanced 'precision' medicine Olaparib.

We discovered MRNIP - a novel cellular factor that acts in a similar way to the BRCA genes, and which we have found also suppresses DNA gaps in Cisplatin and Olaparib-treated cancer cells. We have used a technique called CRISPR to delete the MRNIP gene, and discovered that cells lacking MRNIP are sensitive to both these drugs and accumulate higher levels of DNA gaps and breakage following treatment. We can reverse this breakage and sensitivity by preventing the formation of DNA gaps in cells lacking MRNIP.

Our studies also indicate that most normal and cancer cells contain MRNIP. However, we find that a subset of ovarian cancer cells have no detectable MRNIP. This raises the possibility that certain patients suffer from cancers that lack MRNIP, and who may therefore respond well to particular treatments. MRNIP status may therefore prove a useful tool in 'precision medicine', in which information about each individual patient and the cancer from which they suffer is used to determine the most effective treatment.

Our strategy is to advance our knowledge about MRNIP on several levels. We want to understand how MRNIP functions, to...

Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyUKRI FLF
CountryUnited Kingdom
CategoryResearch Development
PublishedDecember 01, 2023
Procurement stageActive solicitation
ClosedClosing date not published
StatusClosed — no longer accepting responses
Official sourceView original notice
Last verifiedOctober 10, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Browse Similar Open Opportunities in United Kingdom

Global Travel, Accommodation and Venue Management Services
NEPRO Total Talent
Capital Programme Delivery Framework(s)
Technology Products and Associated Services 3
Technology Products and Associated Services 3
Workforce Solution 2
GMCA 2201 NW Regional Children’s Services Contract
Integrated Partnerships Framework

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.